Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 7/20 | 0.63 |
| ▸ | CDK2 | P24941 | 6/20 | 0.63 |
| ▸ | KDR | P35968 | 4/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | JAK2 | O60674 | 3/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.57 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 5/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | CCNH | P51946 | 1/20 | 0.54 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264579 | 0.85 | CDK2 (0.66) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL1265059 | 0.81 | AURKB (0.57) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL13503014 | 0.81 | PIK3C3 (0.53) | CDK4CDK2KDRGSK3BACVR1 | |
| SCHEMBL3616221 | 0.80 | CDK2 (0.58) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL7466266 | 0.80 | CDK2 (0.63) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL1264652 | 0.80 | JAK2 (0.62) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL7476832 | 0.79 | JAK2 (0.72) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL15212479 | 0.79 | JAK2 (0.76) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL7465716 | 0.78 | ACVR1 (0.70) | CDK4CDK2KDRGSK3BJAK2 | |
| SCHEMBL7469627 | 0.78 | CDK2 (0.64) | CDK4CDK2KDRGSK3BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF | 2011-09-15 | — | — | US | disclosed |
| WO-2010039997-A9 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010039997-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048597-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| WO-2008079933-A2 | HETEROARYL-HETEROARYL COMPOUNDS AS CDK INHIBITORS FOR THE TREATMENT OF CANCER, INFLAMMATION AND VIRAL INFECTIONS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CDK4 2/4885CDK2 4/4885KDR 2397/4885 |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK4, CDK6, CDKN1A | CDK4 1/4885CDK2 6/4885KDR 2162/4885 |
| US-20100048597-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CDK4 2775/4885CDK2 3078/4885KDR 3785/4885 |
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CDK4 2/4885CDK2 4/4885KDR 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.